Literature DB >> 16552353

Peptidoglycan--an endotoxin in its own right?

Anders E Myhre1, Ansgar O Aasen, Christoph Thiemermann, Jacob E Wang.   

Abstract

Studies aimed at dissecting the complex pathophysiology of sepsis with multiple organ failure have traditionally focused on lipopolysaccharide of gram-negative bacteria, which is widely regarded as the classical endotoxin. However, gram-positive sepsis now accounts for up to 50% of all cases, calling for a shift of focus. Peptidoglycan (PepG) is the major cell wall component of gram-positive bacteria and has been increasingly recognized as an important proinflammatory molecule. During gram-positive infections, PepG reaches the circulation by bacterial breakdown or translocation from the intestine. Administration of PepG induces all the classical features of infectious illness and endotoxemia and may cause systemic inflammation with organ failure in animal models. Its potency, however, is crucially dependent on various features of its complex structure. PepG interacts with the innate immune system through receptors mainly expressed on monocytes/macrophages but may induce inflammatory changes in other cell types as well. Among the most extensively studied receptor systems are the nucleotide-binding oligomerization domains, the toll-like receptors, and the PepG recognition proteins. Based on the current available literature, we would like to propose that PepG must be regarded as an endotoxin in its own right and to encourage further work in the field of PepG signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552353     DOI: 10.1097/01.shk.0000191378.55274.37

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  12 in total

Review 1.  Scientific and clinical challenges in sepsis.

Authors:  Luis Ulloa; Michael Brunner; Laura Ramos; Edwin A Deitch
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

2.  Regulation of heme oxygenase-1 gene by peptidoglycan involves the interaction of Elk-1 and C/EBPalpha to increase expression.

Authors:  Chi-Chih Hung; Xiaoli Liu; Min-Young Kwon; Young-Ho Kang; Su Wol Chung; Mark A Perrella
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-03-26       Impact factor: 5.464

3.  Anti-peptidoglycan antibodies and Fcγ receptors are the key mediators of inflammation in Gram-positive sepsis.

Authors:  Dawei Sun; Brent Raisley; Marybeth Langer; Janaki K Iyer; Vidya Vedham; Jimmy L Ballard; Judith A James; Jordan Metcalf; K Mark Coggeshall
Journal:  J Immunol       Date:  2012-07-18       Impact factor: 5.422

4.  Inflammatory cytokine response to Bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking.

Authors:  Janaki K Iyer; Taruna Khurana; Marybeth Langer; Christopher M West; Jimmy D Ballard; Jordan P Metcalf; Tod J Merkel; K Mark Coggeshall
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

5.  Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model.

Authors:  Xizhong Cui; Junwu Su; Yan Li; Joseph Shiloach; Steven Solomon; Jeanne B Kaufman; Haresh Mani; Yvonne Fitz; Jia Weng; Laith Altaweel; Virginia Besch; Peter Q Eichacker
Journal:  Intensive Care Med       Date:  2009-09-15       Impact factor: 17.440

Review 6.  Therapeutic targeting of NOD1 receptors.

Authors:  L Moreno; T Gatheral
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

7.  Binding and Cellular Activation Studies Reveal That Toll-like Receptor 2 Can Differentially Recognize Peptidoglycan from Gram-positive and Gram-negative Bacteria.

Authors:  Jinkeng Asong; Margreet A Wolfert; Kaustabh K Maiti; Douglas Miller; Geert-Jan Boons
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

8.  A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses.

Authors:  Timothy Gatheral; Daniel M Reed; Laura Moreno; Peter J Gough; Bart J Votta; Clark A Sehon; David J Rickard; John Bertin; Eric Lim; Andrew G Nicholson; Jane A Mitchell
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

9.  Endodontic microbiology.

Authors:  L Lakshmi Narayanan; C Vaishnavi
Journal:  J Conserv Dent       Date:  2010-10

10.  Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection.

Authors:  K Ramirez; Y Ditamo; L Rodriguez; W L Picking; M L van Roosmalen; K Leenhouts; M F Pasetti
Journal:  Mucosal Immunol       Date:  2009-11-18       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.